“[Full FDA clearance has not yet been achieved, but] there are no regulatory hurdles except supplemental approvals and regular batch release, ... and the fact that we have to finish manufacturing (the vaccine).”
“I think with these projections the [Centers for Disease Control and Prevention] will be in a good position to reach the people most in need of the vaccine and additional targets as well.”
